Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04550546
Other study ID # STUDY00004638
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 15, 2021
Est. completion date February 28, 2022

Study information

Verified date June 2022
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the effect of a prescription mouth rinse (Nystatin),an FDA approved drug, on the different types of bacteria in the mouth. Results from this study may help understand the effect that Nystatin oral rinse has on certain types of oral bacteria, which may also cause tooth decay.


Description:

This is a prospective, single-arm clinical trial of patients diagnosed with oral candidiasis. designed clinical study. All study participants will have positive oral Candida detection with sufficient oral Candida burden to meet the laboratory criteria for a diagnosis of oral candidiasis (≥ 400 CFU/mL of salivary Candida, a standard that was established by Dr. Epstein at the Department of Oral Diagnosis and Department of Microbiology and Immunology at the University of Washington in 1980). All study participants will receive treatment for oral candidiasis using nystatin suspension (Brand name: Mycostatin), and be instructed to rinse the mouth with (6ml of 600,000 U/mL) nystatin suspension, followed by spitting out the suspension, at the frequency of four times per day, for a period of 1 week. The oral microbial changes including fungal and cariogenic bacteria (e.g. S. mutans) will be monitored immediately (within 7 days) and 3-months following the completion of the 1-week Nystatin application. Detailed inclusion and exclusion criteria and methods see below.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 28, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Willing to participate in this study and able to come for follow-up appointments. - Has positive oral Candida detection and the amount of oral Candida meet the laboratory criteria for diagnosing oral Candidiasis (>= 400 colony forming unit in saliva). - Has = 10,000 CFU/mL of S. mutans in the saliva (justification: individuals with = 10,000 CFU/mL salivary S. mutans are considered at elevated risk for dental caries). - Ability to consent, comply with all study procedures and be available for the duration of the study. Exclusion Criteria: - visible signs of candidiasis on the mucosa or tongue at screening (Patients will be referred for treatment immediately) - Patient with systemic diseases, such as HIV, cancer or diabetes. This will be answered by study participants and further confirmed by using electronic medical record (EPIC) for those participants who have records in the EPIC system. (Justification: patient with systemic diseases is that patients with these conditions are more prone to yeast and bacterial infection) - History of local (oral) or systemic antibiotics or antifungal medication within the last 3 months. This will be answered by study participants and further confirmed by using electronic medical record (EPIC) for those participants who have records in the EPIC system. - Women who are currently pregnant or reported that she is currently breast feeding . A pregnancy test (urine test) will be conducted to exclude participants who are pregnant. Rational of excluding pregnant women and women are currently breastfeeding their children: Nystatin oral suspension is classified as FDA pregnancy risk category C. It's also unknown whether nystatin is excreted in human milk.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nystatin
600,000 U/mL of nystatin in a rinse suspension

Locations

Country Name City State
United States Eastman Dental Institute Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in S. Mutans carriage Subjects' whole non-stimulated saliva samples will be collected by spitting into a sterilized 50ml centrifuge tube. S. mutans will be isolated using Mitis Salivarius with Bacitracin selective medium (37°C for 48h) and identified by colony morphology. S. mutans carriage following nystatin suspension oral application using the colony forming unit and scoring (1: no detection, 2: 1-10,000 CFU/mL; 3: >10,000 CFU/mL). Higher scores indicate worse outcome. baseline to 3 months
Secondary Mean C Albicans carriage Subjects' whole non-stimulated saliva samples will be collected by spitting into a sterilized 50ml centrifuge tube. BBLTM CHROMagarTM Candida (BD, Sparks, MD, USA) will be used to isolate C. albicans (37°C for 48h). This medium permits presumptive identification of several clinically important Candida species including C. albicans based on colony color and morphology. C. albicans detection and carriage following nystatin suspension oral application using colony forming unit and scoring (1: no detection, 2: 1-400 CFU/mL; 3: >400 CFU/mL). baseline to 3 months
Secondary Mean change in plaque index Dental plaque status will be assessed using the Plaque Index. Each of the four gingival areas of the tooth will be given a score from 0-3. A score of 0 indicates no plaque in the gingival area, a score of 1 indicates the presence of a film of plaque adhering to the free gingival margin, a score of 2 indicates moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and or adjacent tooth, a score of 3 indicates abundance of soft matter within the gingival pocket and or on the gingival margin and adjacent tooth structure. The scores of each tooth surface will be added and divided by the number of teeth examined to obtain the plaque index score. Higher scores indicate worse outcome baseline to 3 months
Secondary Mean change in number of bleeding on probing sites Bleeding on probing (BOP) will be evaluated to reflect the periodontal status. With a periodontal probe, the periodontal tissue will be assessed to the bottom of the clinical pocket or sulcus. No extra effort will be made to apply a pressure. If bleeding occurs within 10-15 seconds after probing, the positive mark will be recorded on the form. Interproximal sites for every existing tooth, except the third molars, will be scored both from the buccal and the lingual sides. Due to the different numbers of existing teeth for each subject, the change in numbers of BOP sites will be measured and compared. baseline to 3 months
Secondary Mean change in diversity as measured by the Shannon Index We will use established methods to perform the oral microbiome sequencing and related bioinformatics analysis. Genomic DNA from clinical samples will be extracted. The bacterial 16S rRNA V1-V3 hypervariable region and fungal ITS region will be amplified and sequenced on an Illumina MiSeq. Absolute abundance of bacteria and fungi in each sample will be determined by quantitative real-time PCR using 16s and ITS primers, probe and cloned plasmid standards. Sequence reads will be assessed for quality using Quantitative Insights into Microbial Ecology software. USearch will be used to identify specific bacteria/fungi or operational taxonomic units using the GreenGenes and UNITE databases of reference sequences. Bacterial diversity within each sample (alpha diversity) will be computed as the Shannon Index. Equitability assumes a value between 0 and 1 with 1 being complete evenness. baseline to 3 months
Secondary Mean change in diversity as measured by the Bray-Curtis dissimilarity index We will use established methods to perform the oral microbiome sequencing and related bioinformatics analysis. Genomic DNA from clinical samples will be extracted. The bacterial 16S rRNA V1-V3 hypervariable region and fungal ITS region will be amplified and sequenced on an Illumina MiSeq. Absolute abundance of bacteria and fungi in each sample will be determined by quantitative real-time PCR using 16s and ITS primers, probe and cloned plasmid standards. Sequence reads will be assessed for quality using Quantitative Insights into Microbial Ecology software. USearch will be used to identify specific bacteria/fungi or operational taxonomic units using the GreenGenes and UNITE databases of reference sequences. Bacterial diversity between samples (beta diversity) will be computed as the Bray-Curtis dissimilarity index. The Bray-Curtis dissimilarity is a number between 0 (the two sites share all the same species) and 1 (they do not share any species). baseline to 3 months
See also
  Status Clinical Trial Phase
Completed NCT04127929 - Investigation of Glass Carbomer Performance N/A
Completed NCT04769882 - Er:YAG Laser Effects on Microbial Population in Conservative Dentistry N/A
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Active, not recruiting NCT04475679 - Clinical Evaluation of Adhese Universal DC in the Indirect Restorative Therapy N/A
Completed NCT05438381 - Comparison of Clinical and Radiographic Outcomes of SMART Technique vs ART in Primary Molars N/A
Not yet recruiting NCT03037814 - Clinical Performance of Restorative Materials in Primary Teeth N/A
Active, not recruiting NCT05202665 - Resin Infiltration and Fluoride Varnish Lesion Arresting Efficacy on Non-cavitated Proximal Lesion N/A
Terminated NCT01147835 - Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers N/A
Not yet recruiting NCT04033263 - Maintaining Oral Health With Bio-products N/A
Enrolling by invitation NCT04438252 - Evaluation of Reliability of CarieScan PRO Compared With Digital Radiograph and ICDAS-II in Detection of Carious Lesions N/A
Not yet recruiting NCT03609034 - Knowledge, Attitude and Practice of a Group of Egyptian Dental Interns Toward Caries Risk Assessment
Completed NCT02912000 - TEACH: Technology Evaluation to Address Child Health N/A
Completed NCT02473107 - Impact of Detecting Initial and Active Caries Lesions in Primary Teeth N/A
Active, not recruiting NCT02537184 - Impact of Two Recall Intervals on Dental Caries Incidence and Other Outcomes of Preschool Children N/A
Completed NCT01950546 - Nanosilver Fluoride to Prevent Dental Biofilms Growth Phase 1
Recruiting NCT02734420 - Effect of Photodynamic Therapy With Low-level Laser on Infected Dentin in Primary Teeth: A Controlled Clinical Trial Phase 1
Completed NCT02020681 - Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions N/A
Completed NCT02234609 - Effectiveness of Modified Class IV Atraumatic Restorative Treatment N/A
Completed NCT02426619 - Arresting Active Dental Caries in Preschool Children by Topical Fluorides Phase 2/Phase 3
Completed NCT01268605 - Postoperative Hypersensitivity Randomized Comparative Effectiveness Research Trial Phase 3